DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Emend (Aprepitant) - Summary



EMEND (aprepitant) is a substance P/neurokinin 1 (NK1) receptor antagonist.

EMEND, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin (see DOSAGE AND ADMINISTRATION).

See all Emend indications & dosage >>


Media Articles Related to Emend (Aprepitant)

Scientists opens black box on bacterial growth in cystic fibrosis lung infection
Source: Cystic Fibrosis News From Medical News Today [2014.10.22]
Researchers from the University of Copenhagen have shown for the first time how bacteria can grow directly in the lungs of Cystic fibrosis patients, giving them the opportunity to get tremendous...

Review of cannabis research since 1993
Source: Schizophrenia News From Medical News Today [2014.10.08]
In the past 20 years recreational cannabis use has grown tremendously, becoming almost as common as tobacco use among adolescents and young adults, and so has the research evidence.

Nausea and Vomiting
Source: MedicineNet Anaphylaxis Specialty [2014.07.09]
Title: Nausea and Vomiting
Category: Diseases and Conditions
Created: 1/31/2005 8:21:00 AM
Last Editorial Review: 7/9/2014 12:00:00 AM

more news >>

Published Studies Related to Emend (Aprepitant)

Pilot study of aprepitant for prevention of post-ERCP pancreatitis in high risk patients: a phase II randomized, double-blind placebo controlled trial. [2012]
patients... CONCLUSIONS: Aprepitant did not lower incidence of post-ERCP pancreatitis in this

Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study. [2012]
of cisplatin combination chemotherapy for testicular cancer... CONCLUSION: There was a significant improvement in CR rate with aprepitant

Randomized, double-blind comparison of oral aprepitant alone compared with aprepitant and transdermal scopolamine for prevention of postoperative nausea and vomiting. [2012]
and vomiting (PONV) treated with oral aprepitant with or without scopolamine... CONCLUSIONS: This trial evaluating the effectiveness of aprepitant alone and in

Aprepitant plus ondansetron compared with ondansetron alone in reducing postoperative nausea and vomiting in ambulatory patients undergoing plastic surgery. [2012]
outpatient plastic surgery... CONCLUSION: In patients undergoing plastic surgery, the addition of aprepitant to

Aprepitant Plus Ondansetron Compared to Ondansetron Alone in Reducing Postoperative Nausea and Vomiting in Ambulatory Patients Undergoing Plastic Surgery. [2011.10.07]
BACKGROUND:: Postoperative nausea and vomiting (PONV) is a major challenge in the peri-operative setting. The incidence can be as high as 80%, and the majority of PONV symptoms among out-patients occur after discharge. This study evaluated the efficacy of an NK1 receptor antagonist (aprepitant) in reducing PONV for up to forty-eight hours in patients undergoing outpatient plastic surgery... CONCLUSIONS:: In patients undergoing plastic surgery, the addition of aprepitant to ondansetron significantly decreases postoperative vomiting rates and nausea severity for up to 48 hours postoperatively. LEVEL OF EVIDENCE:: Level 2 single-centered prospective randomized controlled therapeutic trial.

more studies >>

Clinical Trials Related to Emend (Aprepitant)

Efficacy of Aprepitant (Emend´┐Ż) in Children [Not yet recruiting]
The purpose of this study is to find out whether or not adding aprepitant(Emend«) to the standard therapy will help children who receive chemotherapy to have less nausea and vomiting.

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3) [Recruiting]
This study will determine the appropriate dosing regimen of aprepitant and fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric participants from 0 months to 17 years of age.

Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children Under 18 Years of Age (MK-0517-029 AM3) [Recruiting]
The purpose of this study is to determine the appropriate dosing regimen of fosaprepitant, when administered with ondansetron (with or without dexamethasone), for the prevention of CINV in children from birth to 17 years of age. Fosaprepitant is a prodrug to aprepitant.

Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide [Not yet recruiting]
The objectives of the study are: 1) to assess the Chemotherapy Induced Nausea and Vomiting (CINV) efficacy and toxicity of Aprepitant in combination with Ondansetron vs Ondansetron alone in preventing acute CINV in brain tumor patients during the acute period (first 24 hours) of receiving 5 day temozolomide therapy; and 2) to assess the efficacy of Aprepitant in combination with Ondansetron vs Ondansetron alone in preventing delayed CINV (day 2-5).

Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial [Recruiting]
The object of this study is to evaluate the superiority of aprepitant therapy with a 5HT3-receptor antagonist, dexamethasone and aprepitant compared to standard therapy with a 5HT3-receptor antagonist and dexamethasone for prevention of nausea and vomiting in first course chemotherapy.

more trials >>

Reports of Suspected Emend (Aprepitant) Side Effects

Nausea (24)Dyspnoea (18)Encephalopathy (18)Drug Interaction (16)Renal Failure Acute (14)Vomiting (9)Convulsion (9)Dehydration (9)Neutropenia (9)Septic Shock (9)more >>

Page last updated: 2014-10-22

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014